Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

Betsy Goodfellow | July 10, 2023 | News story | Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix 

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement is for the investigational, potential first-in-class radioenhancer NBTXR3.

NBTXR3 is currently in several studies assessing its safety and efficacy, including the global phase 3 NANORAY-312 study which is evaluating the treatment for patients with locally advanced head and neck cancer. NBTXR3 is also being assessed for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for the treatment of metastatic cancers.

Under the terms of the agreement, Nanobiotix will grant Janssen a worldwide license for the development and commercialisation of NBTXR3, in collaboration with the Interventional Oncology R&D Unit of Johnson & Johnson. Nanobiotix will receive near-term cash and operational support valued up to $60m, including an upfront cash licensing fee of $30m and regulatory and development support for study NANORAY-312 up to $30m, provided at Janssen’s discretion.

Laurent Levy, chairman of Nanobiotix’s executive board, commented: “As pioneers in the field of nanotherapeutics for the past 20 years, we knew that the true impact of our innovation in oncology would be in its potential to reach millions of patients around the world. For that, we needed to find the right partner, at the right time, with proven global development and commercialisation capabilities. We are delighted to collaborate with Janssen as we aim to improve the lives of patients with cancer around the world.”

Bart van Rhijn, Nanobiotix’s chief financial officer, added: “We expect this agreement, and the collaboration it enables, to further drive the expansion of NBTXR3 development and accelerate the realisation of its promise for patients in need. We look forward to maximising the value of NBTXR3 for our global stakeholders.”

Betsy Goodfellow

Related Content

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a …

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …


Janssen submits sNDA to FDA for full approval of Balversa

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …

Latest content